Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 10—October 2023
Research

Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States

Scott A. NabityComments to Author , Suzanne M. Marks, Neela D. Goswami, Shona R. Smith, Evan Timme, Sandy F. Price, Lon Gross, Julie L. Self, Katelynne Gardner Toren, Masahiro Narita, Donna H. Wegener, Shu-Hua Wang, and for the National Tuberculosis Controllers Association/CDC TB-COVID-19 Collaboration1
Author affiliations: California Department of Public Health, Richmond, California, USA (S.A. Nabity); Centers for Disease Control and Prevention, Atlanta, USA (S.A. Nabity, S.M. Marks, N.D. Goswami, S.F. Price, L. Gross, J.L. Self); Michigan Department of Health and Human Services, Lansing, Michigan, USA (S.R. Smith); Arizona Department of Health Services, Phoenix, Arizona, USA (E. Timme); Public Health–Seattle & King County, Seattle, Washington, USA (K. Gardner Toren, M. Narita); University of Washington, Seattle (M. Narita); National Tuberculosis Controllers Association, Atlanta (D.H. Wegener); The Ohio State University College of Medicine, Columbus, Ohio, USA (S.-H. Wang)

Main Article

Table 3

Adjusted log-binomial risk factors associated with 48 deaths among 288 persons with TB–COVID-19 in 2020, 24 US jurisdictions*

Characteristic No. (%) deaths‡ uPR (95% CI) aPR (95% CI)
Timing of TB and COVID-19 diagnoses†
>90 d 9 (8.6) Referent Referent
<90 d
 39 (21.3)
 2.5 (1.3‒4.9)
 2.3 (1.1‒4.8)
Age at TB diagnosis, y
<44 <5 Referent Referent
45‒64 16 (18.0) 6.7 (2.0‒22.3) 5.6 (1.6‒19.8)
65‒74 11 (23.4) 8.7 (2.6‒29.9) 8.6 (2.4‒31.3)
75‒85 13 (40.6) 15.2 (4.6‒50.0) 12.6 (3.5‒45.7)
>85
 5 (62.5)
 23.3 (6.8‒80.5)
 25.0 (6.9‒91.1)
Immunocompromising condition, non-HIV§
No 39 (14.6) Referent Referent
Yes 9 (45.0) 3.1 (1.8‒5.4) 2.7 (1.1‒6.4)

*Model adjusted for other variables in the table. NTSS outcomes updated as of September 23, 2022. Five with missing outcome; there were no missing values for days between diagnoses, age, or immunocompromising condition (non-HIV). Puerto Rico and Los Angeles County excluded (remainder of California included) because of incompleteness of outcomes data. aPR, adjusted prevalence ratio; TB, tuberculosis; TB–COVID-19, diagnosed with both TB and COVID-19 within 180 days; uPR, unadjusted prevalence ratio. †Days between TB diagnosis and COVID-19 diagnosis, regardless of which was diagnosed first. †Percentage is the number of persons with TB–COVID-19 with the characteristic who died divided by the total number of persons with TB–COVID-19 with that characteristic. §Non-HIV immunocompromising condition attributable to medical conditions, such as hematologic or reticuloendothelial malignancies (e.g., leukemia, Hodgkin’s lymphoma, carcinoma of the head or neck), or immunosuppressive therapy, such as prolonged use of high-dose adrenocorticosteriods (e.g., prednisone), but not including immunocompromising condition related to HIV infection.

Main Article

1Group members are listed at the end of this article.

Page created: August 08, 2023
Page updated: September 20, 2023
Page reviewed: September 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external